Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

Open Access 01-03-2008 | Original Article

Variations in ¹²³I-metaiodobenzylguanidine (MIBG) late heart mediastinal ratios in chronic heart failure: a need for standardisation and validation

Authors: Hein J. Verberne, Jan B. A. Habraken, Berthe L. F. van Eck-Smit, Denis Agostini, Arnold F. Jacobson

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 3/2008

Abstract

Background

There is lack of validation and standardisation of acquisition parameters for myocardial ¹²³I-metaiodobenzylguanidine (MIBG). This lack of standardisation hampers large scale implementation of ¹²³I-MIBG parameters in the evaluation of patients with chronic heart failure (CHF).

Methods

In a retrospective multi-centre study ¹²³I-MIBG planar scintigrams obtained on 290 CHF patients (82% male; 58% dilated cardiomyopathy; New York Heart Association [NYHA classification] > I) were reanalysed to determine the late heart-to-mediastinum ratio (H/M).

Results

There was a large variation in acquisition parameters. Multivariate forward stepwise regression showed that a significant proportion (31%, p < 0.001) of the variation in late H/M could be explained by a model containing patient-related variables and acquisition parameters. Left ventricular ejection fraction (p < 0.001), type of collimation (p < 0.001), acquisition duration (p = 0.001), NYHA class (p = 0.028) and age (p = 0.034) were independent predictors of late H/M.

Conclusions

Acquisitions parameters are independent contributors to the variation of semi-quantitative measurements of cardiac ¹²³I-MIBG uptake. Improved standardisation of cardiac ¹²³I-MIBG imaging parameters would contribute to increased clinical applicability for this procedure.

Sisson JC, Shapiro B, Meyers L, Mallette S, Mangner TJ, Wieland DM, et al. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med 1987;28:1625–36.PubMed

Kline RC, Swanson DP, Wieland DM, Thrall JH, Gross MD, Pitt B, et al. Myocardial imaging in man with I-123 meta-iodobenzylguanidine. J Nucl Med 1981;22:129–32.PubMed

Merlet P, Valette H, Dubois-Rande JL, Moyse D, Duboc D, Dove P, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992;33:471–7.PubMed

Merlet P, Benvenuti C, Moyse D, Pouillart F, Dubois-Rande JL, Duval AM, et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med 1999;40:917–23.PubMed

Momose M, Kobayashi H, Iguchi N, Matsuda N, Sakomura Y, Kasanuki H, et al. Comparison of parameters of 123I-MIBG scintigraphy for predicting prognosis in patients with dilated cardiomyopathy. Nucl Med Commun 1999;20:529–35.PubMedCrossRef

Cohen-Solal A, Esanu Y, Logeart D, Pessione F, Dubois C, Dreyfus G, et al. Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: relationship with peak oxygen uptake and prognosis. J Am Coll Cardiol 1999;33:759–66.PubMedCrossRef

Wakabayashi T, Nakata T, Hashimoto A, Yuda S, Tsuchihashi K, Travin MI, et al. Assessment of underlying etiology and cardiac sympathetic innervation to identify patients at high risk of cardiac death. J Nucl Med 2001;42:1757–67.PubMed

Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure. J Nucl Med 2002;43:1279–85.PubMed

Yamada T, Shimonagata T, Fukunami M, Kumagai K, Ogita H, Hirata A, et al. Comparison of the prognostic value of cardiac iodine-123 metaiodobenzyl-guanidine imaging and heart rate variability in patients with chronic heart failure: a prospective study. J Am Coll Cardiol 2003;41:231–8.PubMedCrossRef

10.

Kyuma M, Nakata T, Hashimoto A, Nagao K, Sasao H, Takahashi T, et al. Incremental prognostic implications of brain natriuretic peptide, cardiac sympathetic nerve innervation, and noncardiac disorders in patients with heart failure. J Nucl Med 2004;45:155–63.PubMed

11.

Nakata T, Wakabayashi T, Kyuma M, Takahashi T, Tsuchihashi K, Shimamoto K. Cardiac metaiodobenzylguanidine activity can predict the long-term efficacy of angiotensin-converting enzyme inhibitors and/or beta-adrenoceptor blockers in patients with heart failure. Eur J Nucl Med Mol Imaging 2005;32:186–94.PubMedCrossRef

12.

Arora R, Ferrick KJ, Nakata T, Kaplan RC, Rozengarten M, Latif F, et al. I-123 MIBG imaging and heart rate variability analysis to predict the need for an implantable cardioverter defibrillator. J Nucl Cardiol 2003;10:121–31.PubMedCrossRef

13.

Paul M, Schafers M, Kies P, Acil T, Schafers K, Breithardt G, et al. Impact of sympathetic innervation on recurrent life-threatening arrhythmias in the follow-up of patients with idiopathic ventricular fibrillation. Eur J Nucl Med Mol Imaging 2006;33:866–70.PubMedCrossRef

14.

Verberne HJ, Feenstra C, de Jong WM, Somsen GA, van Eck-Smit BL, Busemann Sokole E. Influence of collimator choice and simulated clinical conditions on 123I-MIBG heart/mediastinum ratios: a phantom study. Eur J Nucl Med Mol Imaging 2005;32:1100–7.PubMedCrossRef

15.

Agostini D, Verberne HJ, Povinec P, Burchert W, Sambuceti G, Knuuti J, et al. Utility of ¹²³I-MIBG scintigraphy in subjects with heart failure for assessment of risk for a major cardiac event: a European multi-center study. Circulation 2006;114 Suppl II:574.

16.

Suwa M, Otake Y, Moriguchi A, Ito T, Hirota Y, Kawamura K, et al. Iodine-123 metaiodobenzylguanidine myocardial scintigraphy for prediction of response to beta-blocker therapy in patients with dilated cardiomyopathy. Am Heart J 1997;133:353–8.PubMedCrossRef

17.

Estorch M, Flotats A, Serra-Grima R, Mari C, Prat T, Martin JC, et al. Influence of exercise rehabilitation on myocardial perfusion and sympathetic heart innervation in ischaemic heart disease. Eur J Nucl Med 2000;27:333–9.PubMedCrossRef

18.

Parthenakis FI, Prassopoulos VK, Koukouraki SI, Zacharis EA, Diakakis GF, Karkavitsas NK, et al. Segmental pattern of myocardial sympathetic denervation in idiopathic dilated cardiomyopathy: relationship to regional wall motion and myocardial perfusion abnormalities. J Nucl Cardiol 2002;9:15–22.PubMedCrossRef

19.

Lanza GA, Giordano A, Pristipino C, Calcagni ML, Meduri G, Trani C, et al. Abnormal cardiac adrenergic nerve function in patients with syndrome X detected by [123I]metaiodobenzylguanidine myocardial scintigraphy. Circulation 1997;96:821–6.PubMed

20.

Wichter T, Matheja P, Eckardt L, Kies P, Schafers K, Schulze-Bahr E, et al. Cardiac autonomic dysfunction in Brugada syndrome. Circulation 2002;105:702–6.PubMedCrossRef

21.

Inoue Y, Suzuki A, Shirouzu I, Machida T, Yoshizawa Y, Akita F, et al. Effect of collimator choice on quantitative assessment of cardiac iodine 123 MIBG uptake. J Nucl Cardiol 2003;10:623–32.PubMedCrossRef

22.

Dobbeleir AA, Hambye AS, Franken PR. Influence of high-energy photons on the spectrum of iodine-123 with low- and medium-energy collimators: consequences for imaging with 123I-labelled compounds in clinical practice. Eur J Nucl Med 1999;26:655–8.PubMedCrossRef

23.

Somsen GA, Verberne HJ, Fleury E, Righetti A. Normal values and within-subject variability of cardiac I-123 MIBG scintigraphy in healthy individuals: implications for clinical studies. J Nucl Cardiol 2004;11:126–33.PubMedCrossRef

24.

Byrne EA, Fleg JL, Vaitkevicius PV, Wright J, Porges SW. Role of aerobic capacity and body mass index in the age-associated decline in heart rate variability. J Appl Physiol 1996;81:743–50.PubMed

25.

Colosimo A, Giuliani A, Mancini AM, Piccirillo G, Marigliano V. Estimating a cardiac age by means of heart rate variability. Am J Physiol Heart Circ Physiol 1997;273:H1841–H1847.

26.

Craft N, Schwartz JB. Effects of age on intrinsic heart rate, heart rate variability, and AV conduction in healthy humans. Am J Physiol Heart Circ Physiol 1995;268:H1441–H1452.

27.

Esler MD, Thompson JM, Kaye DM, Turner AG, Jennings GL, Cox HS, et al. Effects of aging on the responsiveness of the human cardiac sympathetic nerves to stressors. Circulation 1995;91:351–8.PubMed

28.

Kingwell BA, Thompson JM, Kaye DM, McPherson GA, Jennings GL, Esler MD. Heart rate spectral analysis, cardiac norepinephrine spillover, and muscle sympathetic nerve activity during human sympathetic nervous activation and failure. Circulation 1994;90:234–40.PubMed

29.

Laitinen T, Hartikainen J, Vanninen E, Niskanen L, Geelen G, Lansimies E. Age and gender dependency of baroreflex sensitivity in healthy subjects. J Appl Physiol 1998;84:576–83.PubMed

30.

Tsuji H, Venditti FJ Jr, Manders ES, Evans JC, Larson MG, Feldman CL, et al. Determinants of heart rate variability. J Am Coll Cardiol 1996;28:1539–46.PubMedCrossRef

31.

Shimada K, Kitazumi T, Sadakane N, Ogura H, Ozawa T. Age-related changes of baroreflex function, plasma norepinephrine, and blood pressure. Hypertension 1985;7:113–7.PubMed

32.

Cowie MR, Rawles JM. A modified method of quantifying the carotid baroreceptor-heart rate reflex in man: the effect of age and blood pressure. Clin Sci (Lond) 1989;77:223–8.

33.

Iwase S, Mano T, Watanabe T, Saito M, Kobayashi F. Age-related changes of sympathetic outflow to muscles in humans. J Gerontol 1991;46:M1–M5.PubMed

34.

Randall O, Esler M, Culp B, Julius S, Zweifler A. Determinants of baroreflex sensitivity in man. J Lab Clin Med 1978;91:514–9.PubMed

35.

Somsen GA, Borm JJ, Dubois EA, Schook MB, van der Wall EE, van Royen EA. Cardiac 123I-MIBG uptake is affected by variable uptake in reference regions: implications for interpretation in clinical studies. Nucl Med Commun 1996;17:872–6.PubMedCrossRef

36.

Estorch M, Carrio I, Berna L, Lopez-Pousa J, Torres G. Myocardial iodine-labeled metaiodobenzylguanidine 123 uptake relates to age. J Nucl Cardiol 1995;2:126–32.PubMed

37.

Merlet P, Pouillart F, Dubois-Rande JL, Delahaye N, Fumey R, Castaigne A, et al. Sympathetic nerve alterations assessed with 123I-MIBG in the failing human heart. J Nucl Med 1999;40:224–31.PubMed

38.

Agostini D, Belin A, Amar MH, Darlas Y, Hamon M, Grollier G, et al. Improvement of cardiac neuronal function after carvedilol treatment in dilated cardiomyopathy: a 123I-MIBG scintigraphic study. J Nucl Med 2000;41:845–51.PubMed

39.

Visser JJ, Busemann Sokole E, Verberne HJ, Habraken JB, van de Stadt HJ, Jaspers JE, et al. A realistic 3-D gated cardiac phantom for quality control of gated myocardial perfusion SPET: the Amsterdam gated (AGATE) cardiac phantom. Eur J Nucl Med Mol Imaging 2004;31:222–8.PubMed

40.

Britton KE, Busemann Sokole E. COST B2: why and wherefore. Eur J Nucl Med 1992;19:563–8.CrossRef

Title: Variations in 123I-metaiodobenzylguanidine (MIBG) late heart mediastinal ratios in chronic heart failure: a need for standardisation and validation
Authors: Hein J. Verberne
Jan B. A. Habraken
Berthe L. F. van Eck-Smit
Denis Agostini
Arnold F. Jacobson
Publication date: 01-03-2008
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 3/2008
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-007-0611-2

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Variations in ¹²³I-metaiodobenzylguanidine (MIBG) late heart mediastinal ratios in chronic heart failure: a need for standardisation and validation

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2008

Evaluating the accuracy of perfusion/metabolism (SPET/PET) ratio in seizure localization

FDG uptake by the bone marrow in NSCLC patients is related to TGF-β but not to VEGF or G-CSF serum levels

Discrepancy between glucose metabolism and sympathetic nerve terminals in a patient with metastatic paraganglioma

Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systems

EANM-ESR white paper on multimodality imaging

Biodistribution and radiation dosimetry of the norepinephrine transporter radioligand (S,S)-[18F]FMeNER-D2: a human whole-body PET study